Literature DB >> 26455289

Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review.

Ourania Nicolatou-Galitis1, Evangelia Razis2, Dimitra Galiti3, Evangelos Galitis4, Stefanos Labropoulos2, Antonis Tsimpidakis2, Joseph Sgouros5, Athanasios Karampeazis6, Cesar Migliorati7.   

Abstract

OBJECTIVE: We present clinical and radiologic data of periodontal tissue involvement preceding the appearance of osteonecrosis of the jaw (ONJ) in 5 patients with solid tumors, who received antiresorptives alone or in combination with targeted therapies. STUDY
DESIGN: Five patients with osteonecrosis before dental extraction were studied.
RESULTS: Periodontal involvement was evidenced by pain, bleeding, fistula, purulence, swelling, periodontal pocket, and tooth mobility. Combined endoperiodontal lesions were considered in 1 patient. Duration of symptoms before ONJ diagnosis lasted 8 to 24 weeks. Routine therapy was performed in 2 of 5 patients. Widening of the periodontal ligament was observed in 4 patients, and dense alveolar bone was seen in 1 patient. Local complications of ONJ required dental extractions in 4 of 5 patients. Spontaneous tooth exfoliation was observed in 1 patient. Alveolar bone biopsies, after the extraction in 2 patients, confirmed osteonecrosis. Osteonecrosis healed in 2 patients--1 after the dental extraction and 1 after 3 dental extractions and surgical debridement. Postextraction socket healed in 1 patient, and the area with exposed bone remained asymptomatic. Osteonecrosis progressed in 2 patients.
CONCLUSIONS: Clinical and radiologic signs of periodontal tissue involvement, before dental extraction in patients treated with antiresorptives alone or in combination with targeted therapy, may represent developing osteonecrosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26455289     DOI: 10.1016/j.oooo.2015.08.007

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  10 in total

1.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

2.  Apical surgery in cancer patients receiving high-dose antiresorptive medication-a retrospective clinical study with a mean follow-up of 13 months.

Authors:  Sanne Werner Moeller Andersen; Simon Storgaard Jensen; Morten Schiodt
Journal:  Oral Maxillofac Surg       Date:  2020-09-24

3.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

4.  The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab.

Authors:  Erofili Papadopoulou; Ourania Nicolatou-Galitis; Ioannis Papassotiriou; Helena Linardou; Aikaterini Karagianni; Konstantinos Tsixlakis; Anthi Tarampikou; Kelly Michalakakou; Emmanouil Vardas; Dimitrios Bafaloukos
Journal:  Support Care Cancer       Date:  2019-04-17       Impact factor: 3.603

5.  Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases.

Authors:  Francesco Erovigni; Alessio Gambino; Marco Cabras; Antonella Fasciolo; Silvio Diego Bianchi; Elisa Bellini; Vittorio Fusco
Journal:  Dent J (Basel)       Date:  2016-10-29

Review 6.  Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw.

Authors:  Ha Young Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-10-21

7.  Porphyromonas gingivalis Induces Bisphosphonate-Related Osteonecrosis of the Femur in Mice.

Authors:  Shuxuan Wu; Feng Li; Jingjing Tan; Xiaoling Ye; Yushi Le; Nianke Liu; Vincent Everts; Qilong Wan
Journal:  Front Cell Infect Microbiol       Date:  2022-06-22       Impact factor: 6.073

8.  Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression.

Authors:  Ashraf Z Badros; Mariam Meddeb; Dianna Weikel; Sunita Philip; Todd Milliron; Rena Lapidus; Lisa Hester; Olga Goloubeva; Timothy F Meiller; Emmanuel F Mongodin
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

9.  Osteonecrosis of the jaw (ONJ) in patients who receive Bone Targeting Agents (BTAs): the power of e-learning.

Authors:  Ourania Nicolatou-Galitis; Cesar Migliorati
Journal:  Ecancermedicalscience       Date:  2018-01-23

10.  A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation.

Authors:  Min Jiang; Lixian Liu; Ruiwu Liu; Kit S Lam; Nancy E Lane; Wei Yao
Journal:  BMC Pharmacol Toxicol       Date:  2020-11-13       Impact factor: 2.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.